Distinguishing between primary endocervical and endometrial adenocarcinomas: Is a 2-marker (Vim/CEA) panel enough?

Virchows Archiv

Volumn 456, Issue 4, 2010, Pages 377-386

  Liao, Chiung Ling ^a,b   Hsu, Jeng Dong ^a,b   Lee, Ming Yung ^c   Kok, Lai Fong ^d   Li, Yi Ju ^b   Wang, Po Hui ^a,b   Yao, Chung Chin ^a   Han, Chih Ping ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c PROVIDENCE UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adenocarcinomas; Carcinoembryonic antigen; Endocervical; Endometrial; Estrogen; Immunohistochemistry (IHC); P16INK4a (P16); Progesterone; Tissue microarray; Vimentin

Indexed keywords

AVIDIN; BIOTIN; CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR; TUMOR MARKER; VIMENTIN;

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CARCINOMA; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TISSUE MICROARRAY; TISSUE SECTION; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN ARRAY ANALYSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VIMENTIN;

EID: 77951252655     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0892-x     Document Type: Article

References (28)

1. Lurain JR, Bidus MA, Elkas JC (2007) Uterine cancer, cervical and vaginal cancer. In: Berek RS (ed) Novak's gynecology, 14th edn. Lippincott Williams & Wilkins (LWW), Philadelphia, pp 1343-1402
2. JO Schorge LM Knowles JS Lea 2004 Adenocarcinoma of the cervix Curr Treat Options in Oncol 5 119 127 10.1007/s11864-004-0044-0 (Pubitemid 38915116)
3. Han CP, Lee MY, Kok LF, et al (2010) A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/ p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet in press, doi: 10.1007/s00404-009-1151-8
4. INK4a immunohistochemistry based on independent nucleic staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study Mod Path 22 797 806
5. CC Yao LF Kok MY Lee, et al. 2009 Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study Arch Gynecol Obstet 280 3 405 413 10.1007/s00404-008-0859-1 19153755
6. CP Han MY Lee LF Kok, et al. 2009 Adding the p16INK4a-marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study Int J Gynecol Pathol 28 5 489 496 10.1097/PGP. 0b013e31819e8ab4 19696622
7. MH Zweig G Campbell 1993 Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine Clin Chem 39 561 577 1:CAS:528:DyaK3sXktVCitLs%3D 8472349 (Pubitemid 23118304)
8. CE Metz 1978 Basic principles of ROC analysis Semin Nucl Med 8 283 298 10.1016/S0001-2998(78)80014-2 1:STN:280:DyaE1M3kvVyltQ%3D%3D 112681
9. S Kamoi MI AlJuboury MR Akin, et al. 2002 Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint Int J Gynecol Pathol 21 217 223 10.1097/00004347-200207000- 00003 12068166 (Pubitemid 34680337)
10. T Khoury D Tan J Wang, et al. 2006 Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma BMC Clin Pathol 6 1 10.1186/1472-6890-6-1 16409624 (Pubitemid 43305313)
11. CP Han MY Lee SL Tzeng, et al. 2008 Nuclear receptor interaction protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization J Exp Clin Cancer Res 27 25 10.1186/1756-9966-27-25 18673574
12. B Hanley 2007 Variance in multiplex suspension array assays: carryover of microspheres between sample wells J Negat Results Biomed 6 6 10.1186/1477-5751-6-6 17459164 (Pubitemid 46701017)
13. G Bodner MF Schocke F Rachbauer, et al. 2002 Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis Radiology 223 410 416 10.1148/radiol.2232010406 11997546 (Pubitemid 34454319)
14. P Mhawech-Fauceglia F Herrmann W Bshara, et al. 2008 Intraobserver and interobserver variability in distinguishing between endocervical and endometrial adenocarcinoma on problematic cases of cervical curettings Int J Gynecol Pathol 27 431 436 10.1097/PGP.0b013e3181601792 18580323
15. WG McCluggage VP Sumathi HA McBride, et al. 2002 A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas Int J Gynecol Pathol 21 11 15 10.1097/00004347- 200201000-00003 11781517
16. M Wehling 2008 Translational medicine: science or wishful thinking? J Transl Med 6 31 10.1186/1479-5876-6-31 18559092 (Pubitemid 351998269)
17. DJ Dabbs K Sturtz RJ Zaino 1996 Distinguishing endometrial from endocervical adenocarcinoma Hum Pathol 27 172 177 10.1016/S0046-8177(96)90371-8 1:STN:280:DyaK287ptV2gtA%3D%3D 8617459 (Pubitemid 26049471)
18. DH Castrillon KR Lee MR Nucci 2002 Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study Int J Gynecol Pathol 21 4 10 10.1097/00004347-200201000-00002 11781516 (Pubitemid 34008346)
19. A Alkushi J Irving F Hsu, et al. 2003 Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray Virchows Arch 442 271 277 1:STN:280:DC%2BD3s7jt12juw%3D%3D 12647218 (Pubitemid 36399222)
20. Miller RT (2002) Endocervical vs. endometrial adenocarcinoma, THE FOCUS - Immunohistochemistry Jan; 1-2
21. Miller RT (2003) Endocervical vs. endometrial adenocarcinoma: update on useful immunohistochemical markers, THE FOCUS - Immunohistochemistry Apr; 1-2
22. M Reid-Nicholson P Iyengar AJ Hummer 2006 Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis Mod Pathol 8 1091 1100 (Pubitemid 44106724)
23. WG McCluggage D Jenkins 2003 p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma Int J Gynecol Pathol 22 231 235 10.1097/01.PGP.0000055172.04957.2F 1:STN:280: DC%2BD3s3ptF2jtQ%3D%3D 12819388 (Pubitemid 36750403)
24. K Mittal R Soslow WG McCluggage 2008 Application of immunohistochemistry to Gynecologic Pathology Arch Pathol Lab Med 132 402 423 18318583 (Pubitemid 351337535)
25. WG McCluggage 2004 A critical appraisal of the value of immunohistochemistry in diagnosis of uterine neoplasms Adv Anat Pathol 11 162 171 10.1097/00125480-200405000-00004 15096730
26. MA Ansari-Lari A Staebler RJ Zaino, et al. 2004 Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection Am J Surg Pathol 28 160 167 10.1097/00000478-200402000-00002 15043304 (Pubitemid 38124723)
27. WG McCluggage 2004 Re: distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papilloma virus (HPV) DNA detection Am J Surg Pathol 28 974 15223971 (Pubitemid 38856857)
28. CP Han MY Lee YS Tyan 2009 p16(INK4) and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16(INK4)) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study Virchows Arch 455 353 361 10.1007/s00428-009-0826-7 1:CAS:528:DC%2BD1MXhtlagt7fJ 19763614